Avalanche Biotechnologies reports fourth quarter and fiscal 2014 financial results
Avalanche Biotechnologies reported the full year 2014 net loss attributable to common stockholders was $28.6 million, or $2.46 per basic and diluted share,versus a net loss of $5.3 million, or $1.44 per basic and diluted share in 2013. Cash and equivalents as of Dec. 31, 2014 was $159.4 million. March 05, 2015